AntiCoagulants and COGnition
NCT04073316, Phase 4, Unknown, University Hospital, Angers
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | AntiCoagulants and COGnition | ClinicalTrials.gov |
| NCT number | NCT04073316 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 48 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Angers | ClinicalTrials.gov |
| Conditions | Nonvalvular Atrial Fibrillation | ClinicalTrials.gov |
| Interventions | Rivaroxaban 20 MG, Warfarin | ClinicalTrials.gov |
| First posted | 2019-08-29 | ClinicalTrials.gov |
| Last updated | 2022-07-27 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in global cognitive performance | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Global cognitive performance is assessed with Alzheimer's Disease Assessment Scale-cognition score (ADAS-cog). Total scores range from 0-70, with higher scores (≥ 18) indicating greater cognitive impairment. | ClinicalTrials.gov |
| Secondary | Change in executive functions | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Executive functions are assessed with Frontal Assessment Battery score (FAB). | ClinicalTrials.gov |
| Secondary | Change in executive functions | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Executive functions are assessed with digit spans. | ClinicalTrials.gov |
| Secondary | Change in executive functions | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Executive functions are assessed with Trail Making Tests (TMT) parts A and B. | ClinicalTrials.gov |
| Secondary | Change in executive functions | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Executive functions are assessed with Stroop test. | ClinicalTrials.gov |
| Secondary | Change in executive functions | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Executive functions are assessed with the Processing Speed Index. | ClinicalTrials.gov |
| Secondary | Change in episodic memory | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Episodic memory is assessed with Five-word test. The 5-word test studies the recall of a short list. The score of the first immediate recall and the score of the delayed recall should normally be equal to 10. | ClinicalTrials.gov |
| Secondary | Change in independence and autonomy | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Independence and autonomy are assessed with Activities of Daily Living (ADL) score. ADL is an autonomy assessment grid (from 0 to 6) for basic activities of daily living (ADL). The lower the score, the more dependent the patient is. | ClinicalTrials.gov |
| Secondary | Change in independence and autonomy | This outcome is assessed at baseline, 26 and 52 weeks after inclusion. | Independence and autonomy are assessed with the 4-item Instrumental Activities of Daily Living (IADL-PAQUID) score. This test is used to assess the level of dependence in instrumental activities of daily living. The scale ranges from 0 to 4, with 0 indicating total dysautonomy and 4 indicating a totally autonomous person. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)